LogD

Fig. 5.7 Relationship between lipophilicity and unbound renal (squares) and metabolic clearance (triangles) for a range of neutral drugs in man.

creasing log D and this becomes the major clearance route of lipophilic compounds. Noticeably, considering the logarithmic scale in Figure 5.7, overall clearance declines with decreasing lipophilicity. The lowest clearances, achieved by the combined renal and metabolic processes, are observed below log D74 values of 0 where metabolic clearance is negligible. This apparent advantage needs to be offset against the disadvantages of reliance on gastrointestinal absorption via the aqueous pore pathway that will tend to predominate for hydrophilic compounds. Moreover the actual potency of the compound is also normally affected by lipophilicity with potency tending to increase with increasing lipophilicity [5]. Furthermore as shown previously, volume of distribution also increases with increasing lipophilicity and hence tends to increase the elimination half-life (ty2 = 0.693 x Vd/Cl). Therefore the duration of the drug in the system is a fine balance between the relationship of lipophilicity and its effects on volume of distribution and clearance.

This balance is illustrated by reference to two p-adrenoceptor antagonists, atenolol and propranolol [6]. These have differing physicochemical properties. Atenolol is a hydrophilic compound which shows reduced absorption, low clearance predominantly by the renal route and a moderate volume of distribution. Note that absorption by the paracellular route is still high, due to the small size of this class of agent. In contrast, propranolol, a moderately lipophilic compound, shows high absorption, high clearance via metabolism and a large volume of distribution. Because of this balance of properties both compounds exhibit very similar elimination half-lives. These half-lives are sufficiently long for both drugs to be administered on twice daily

Tab. 5.1 Physicochemical, pharmacological and pharmacokinetic properties for atenolol and propranolol illustrating their interdependence.

D7.4

Affinity (nM)

Absorption (%)

Oral clearance (unbound) mL min-1 kg-1

Volume of distribution (unbound) L kg-1

Half-life (h)

Atenolol

-1.9

100

50

4

0.8

3-5

Propranolol

1.1

4

100

700

51

3-5

Fig. 5.8 Analysis of marketed oral drugs and their lipophilic properties.

Fig. 5.8 Analysis of marketed oral drugs and their lipophilic properties.

(b. d.) dosage regimens due to the relatively flat dose-response curves of this class of agent (Table 5.1).

Propranolol is considerably more potent (albeit less selective) than atenolol. Thus despite a much higher clearance than atenolol, both agents have a daily clinical dose size of around 25-100 mg.

Optimal properties may reside over a span of lipophilicities as illustrated by the p-adrenoreceptor antagonists. However analysis of over 200 marketed oral drugs illustrates the distribution shown in Figure 5.8, where most drugs reside in the "middle ground" of physiochemical properties with log D74 values in the range 0 to 3. This is probably a result of good fortune rather than design, but intuitively it fits with the idea of maximizing oral potency, absorption and duration by balancing intrinsic potency, dissolution, membrane transfer, distribution and metabolism.

References

1 Muller M, Jansen, PLM, Am. J. Physiol. 1997, 272, G1285-G1303.

2 Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT, Xenobiotica. 1995, 25, 185-197.

3 Yabuki M, Mine T, Iba K, Nakatsuka I, Yoshitake A, Drug Metab. Dispos. 1994, 22, 294-297.

4 Smith DA, In: Computer-Assisted Lead Finding and Optimisation (Eds Van de

Waterbeemd H, Testa B, Folkers G), pp. 265-276. Wiley-VCH, Weinheim, 1997.

5 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, Adv. Drug Del. Rev. 1997, 23, 3-25.

6 Yamada Y, Ito K, Nakamura K, Sawada Y, Tatsuji I, Biol. Pharm. Bull. 1993, 16, 1251-1259.

Pharmacokinetics and Metabolism in Drug Design 67 Edited by D. A. Smith, H. van de Waterbeemd, D. K. Walker, R. Mannhold, H. Kubinyi, H. Timmerman I

Copyright © 2001 Wiley-VCH Verlag GmbH ISBNs: 3-527-30197-6 (Hardcover); 3-527-60021-3 (Electronic)

Was this article helpful?

0 0

Post a comment